The appointment of Dr. Renè Lenggenhager to the CovalX Board of Directors

Zurich, Switzerland (June 17th, 2021)

CovalX AG is pleased to announce that Dr. René Lenggenhager has been appointed to the CovalX Board of Directors, effective June 17th, 2021. He was previously CEO of Comet AG, a publicly listed company on the Swiss Stock Exchange, which is a global leader in high-tech components for radio and x-ray. Prior to Comet, Dr. Lenggenhager was Group President of Bruker BioSpin and General Manager of Mettler-Toledo; both positions in the area of advanced analytical tools.

Phillip Bodmer, Chairman of the Board for CovalX AG, has stated that, “We are exceptionally lucky that a person of his caliber, background and experience is joining our BoD.”

Mr. Lenggenhagger has worked with several innovative Swiss start-up companiesand has formal training and experience as a Board Member in Switzerland. He was originally educated as an Electrical Engineer before completing his Dr. sc. Nat. at the ETH in Zurich. He then obtained an MBA from University of St. Gallen and advanced training at INSEAD in Fountainebleau. His expertise includes not only extensive knowledge of scientific instrumentation and management, but also scientific services; all of which could be of direct benefit towards CovalX development plans.


CovalX AG was founded in 2005 and is headquartered in Zurich, Switzerland with the vision to become the leading provider of technology and services in the field of High-Mass MALDI analysis for intact proteins and protein interactions. With support offices in Europe, North America and Asia, CovalX is a global company offering leading products and services for major pharmaceutical companies, as well as academic laboratories worldwide. CovalX is a fast-growing company, developing innovative analysis solutions for the characterization of therapeutic proteins and protein interactions in the life science industry.